Respiratory Research

Table 2 Summary statistics of baseline characteristics for patients with ≥ 5% and < 5% decline in VC at month 3

From: The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial

Characteristics		5% decline in VC at Month 3
		No	Yes	Total*	P-value
Age	Subjects	194	67	261	0.3623
	Mean ± S.D.	65.1 ± 6.5	64.1 ± 7.9	64.9 ± 6.9
BMI	Subjects	194	67	261	0.0011
	Mean ± S.D.	24.7 ± 2.9	23.3 ± 2.9	24.3 ± 3.0
PaO₂	Subjects	192	67	259	0.0047
	Mean ± S.D.	81.5 ± 9.6	78.1 ± 7.9	80.6 ± 9.3
SpO₂	Subjects	193	67	260	0.1114
	Mean ± S.D.	89.1 ± 2.2	88.6 ± 2.2	89.0 ± 2.2
VC	Subjects	194	67	261	0.0036
	Mean ± S.D.	2.51 ± 0.67	2.24 ± 0.63	2.44 ± 0.67
%VC	Subjects	194	67	261	0.0127
	Mean ± S.D.	79.4 ± 17.2	73.3 ± 17.1	77.8 ± 17.3
TLC	Subjects	193	67	260	0.0219
	Mean ± S.D.	3.76 ± 0.92	3.43 ± 1.01	3.68 ± 0.95
%TLC	Subjects	193	67	260	0.0722
	Mean ± S.D.	75.0 ± 15.1	70.6 ± 17.8	73.9 ± 15.9
DLCO	Subject	193	67	260	0.0639
	Mean ± S.D.	9.82 ± 3.23	9.00 ± 3.07	9.61 ± 3.20
%DLCO	Subjects	193	67	260	0.1768
	Mean ± S.D.	54.4 ± 17.8	51.0 ± 18.0	53.6 ± 17.9
KL-6	Subjects	194	67	261	0.4436
	Mean ± S.D.	1308.2 ± 771.0	1401.9 ± 889.2	1332.2 ± 802.3
SP-A	Subjects	194	67	261	0.0281
	Mean ± S.D.	88.0 ± 43.0	108.3 ± 69.7	93.2 ± 51.8
SP-D	Subjects	194	67	261	0.0344
	Mean ± S.D.	223.1 ± 130.5	282.1 ± 210.9	238.2 ± 156.8
H-J classification	Subjects	194	67	261	0.0765
	Mean ± S.D.	2.0 ± 0.7	2.2 ± 0.7	2.1 ± 0.7

* Patients for whom the changes in VC at month 3 couldn't be calculated were deleted from the analysis. The differences in the number of subjects among the variables at column 'Total' were due to missing values at baseline.
TLC, total lung capacity; PaO₂, arterial oxygen tension; SpO₂, oxygen saturation by pulse oximetry; DLCO, diffusing capacity for carbon monoxide; SP-A (or D), Surfactant protein-A (or D); BMI, Body Mass Index.

Back to article page

ISSN: 1465-993X

Contact us

General enquiries: journalsubmissions@springernature.com